Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5845061 | 0.79 | ESR1 (0.56) | ESR1ESR2 | |
| SCHEMBL18144926 | 0.78 | TDP1 (0.55) | TDP1ALDH1A1MAPK1RXRASRD5A2 | |
| SCHEMBL30036421 | 0.78 | TDP1 (0.59) | TDP1ALDH1A1MAPK1RXRASRD5A2 | |
| SCHEMBL8372906 | 0.78 | TDP1 (0.72) | TDP1ALDH1A1MAPK1RXRASRD5A2 | |
| SCHEMBL28452012 | 0.76 | HTR2C (0.48) | ALDH1A1MAPK1SRD5A1ESR1ESR2 | |
| SCHEMBL10506385 | 0.75 | TDP1 (0.52) | TDP1ALDH1A1MAPK1RXRASRD5A2 | |
| SCHEMBL6861402 | 0.75 | ALDH1A1 (0.39) | TDP1ALDH1A1MAPTESR1ESR2 | |
| SCHEMBL22662965 | 0.74 | TDP1 (0.55) | TDP1ALDH1A1MAPK1RXRASRD5A2 | |
| SCHEMBL22663014 | 0.74 | TDP1 (0.55) | TDP1ALDH1A1MAPK1RXRASRD5A2 | |
| SCHEMBL6860944 | 0.74 | TDP1 (0.51) | TDP1ALDH1A1MAPK1RXRASRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6797714-B2 | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION | BAYER PHARMACEUTICALS CORPORATION | 2004-09-28 | — | — | US | disclosed |
| US-20030013705-A1 | Novel carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2003-01-16 | — | — | US | disclosed |
| US-6469031-B1 | USEFUL IN THE TREATMENT OF CONDITIONS SUCH AS HYPER-TRIGLYCERIDAEMIA, HYPERCHOLESTEROLAEMIA AND IN LOWERING HIGH DENSITY LIPOPROTEIN LEVELS AS WELL AS IN THE TREATMENT OF ATHEROSCLEROTIC, CARDIOVASCULAR AND DIABETIC CONDITIONS | BAYER CORPORATION | 2002-10-22 | — | — | US | disclosed |
| EP-1040106-B1 | CARBOXYL SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA 3 ADRENORECEPTOR AGONISTS | BAYER AG (US) | 2002-08-28 | — | — | EP | disclosed |
| EP-1040106-A1 | CARBOXYL SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA 3 ADRENORECEPTOR AGONISTS | Bayer Corporation (US) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999032476-A1 | CARBOXYL SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA 3 ADRENORECEPTOR AGONISTS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013705-A1 | Novel carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | ADRB3, ADRB1, ADRB2 | TDP1 4547/4885ALDH1A1 1345/4885MAPK1 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.